The market will come in five years.
Worn electronics has a golden era in healthcare. Not for nothing. The biggest problem for many implants has always been to get energy.
Dartmouth College researchers have begun to develop a system that will allow the pacemaker and other biomedical implants to work without a battery.
Energy will be acquired directly from the movement of the heart. Scientists have successfully tested the device on animals. The sale should be five years.
The system is described in Advanced Materials Technologies.
Using Heart Movement
Millions of people use a pacemaker, defibrillator, or other implantable device. The disadvantage of all these systems is that they are powered by batteries that need to be changed every five to ten years. They require surgery. This is not a relatively expensive and complicated procedure.
This is why Dartmouth college researchers develop a pacemaker that gets the power directly from the movement of the heart. The most important part of the system is a thin polymer piezoelectric film called PVDF. It is directly connected to the heart.
Piezoelectric substances represent a specific group of materials in which a mechanical charge occurs at mechanical deformation.
Researchers have used material with a normal porous structure to develop, so this effect is even more pronounced. Electricity is generated even with the slightest mechanical movement.
The film can also serve as a sensor for reporting the health of the patient in real time.
"It was very important that the device does not limit the natural functions of the human body," says Lynn Dong, head of the study. "We needed something biocompatible, lightweight, flexible and poorly profiled, so the system not only fits into the current pacemaker structure, but is also suitable for future multifunctionality."
Placing on the market
"We are trying to solve the biggest problem of any implantable biomedical system: how to provide an efficient energy source so the device can work throughout the patient's life without changing the battery," said co-author John J.
Researchers successfully completed the first round of animal studies. It will take another two years to begin testing human patients. If proven, sales should be five years.